HC Wainwright Cuts Emergent Biosolutions (NYSE:EBS) Price Target to $10.00

Emergent Biosolutions (NYSE:EBS) had its target price decreased by HC Wainwright from $12.00 to $10.00 in a research report sent to investors on Monday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Emergent Biosolutions’ Q3 2026 earnings at ($0.75) EPS, Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($4.63) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at $0.23 EPS, Q3 2027 earnings at $0.22 EPS, Q4 2027 earnings at $0.35 EPS and FY2027 earnings at $0.28 EPS.

Several other equities analysts also recently commented on EBS. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Emergent Biosolutions in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.00.

Emergent Biosolutions Stock Up 2.2%

Shares of NYSE:EBS opened at $4.55 on Monday. The company has a fifty day moving average of $7.59 and a 200-day moving average of $8.60. The company has a market capitalization of $233.28 million, a PE ratio of -1.28 and a beta of 2.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. Emergent Biosolutions has a 52-week low of $4.36 and a 52-week high of $14.06.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. The company had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. On average, equities analysts predict that Emergent Biosolutions will post -4.63 EPS for the current fiscal year.

Insider Buying and Selling at Emergent Biosolutions

In other news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares of the company’s stock, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Torren Management LLC acquired a new stake in Emergent Biosolutions during the 4th quarter valued at approximately $37,000. CANADA LIFE ASSURANCE Co acquired a new position in shares of Emergent Biosolutions in the 4th quarter worth approximately $45,000. Legal & General Group Plc bought a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at $31,000. Farther Finance Advisors LLC boosted its stake in shares of Emergent Biosolutions by 361.3% in the 4th quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 4,827 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $53,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions News Roundup

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a $10 price target, implying substantial upside from recent trading levels. The firm projects a return to profitability in 2027, with positive EPS estimates of $0.23 in the second quarter, $0.22 in the third quarter, $0.35 in the fourth quarter and $0.28 for the full year. HC Wainwright Issues Pessimistic Forecast for Emergent BioSolutions Stock Price
• Neutral Sentiment: HC Wainwright expects substantial near-term losses, including estimated EPS of negative $0.75 for the third quarter of 2026, negative $0.64 for the fourth quarter and negative $4.63 for full-year 2026. While the estimates point to a potential recovery in 2027, they also highlight continued earnings volatility and execution risk.
• Negative Sentiment: Levi & Korsinsky announced an investigation into Emergent BioSolutions after the company disclosed a $191.3 million non-cash impairment charge on its NARCAN franchise. Emergent attributed the write-down to increased competition and pricing pressure in naloxone products. The investigation may add legal and reputational uncertainty, although the announcement is an investor solicitation and does not establish wrongdoing. EBS Investor Alert
• Negative Sentiment: Reports highlighting EBS’s slide to a 52-week low reinforce concerns about the impairment, competitive threats to NARCAN and the company’s weak near-term earnings outlook. Why Did EBS Stocks Plummet to 52-Week Lows?

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.